MOGAT2 and metabolic syndrome: Due to their involvement in TG re-synthesis and secretion, it is believed that MOGAT2 and 3, but also DGAT1 are potential therapeutic drug targets for treating diet-induced dyslipidemia and obesity [44,49-51], whereas an activation of PPARα was suggested as the initial regulator [52].